MarketPR
NVDANVIDIA fiscal Q2 revenue doubles to $96.22 billionOct 20WMTWalmart introduces discounted joint membership with Sam's ClubOct 20EARNINGSWedgewood Trims TSMC Position as Semiconductor Crowded Trade UnwindsOct 20EARNINGSS&P 500 tests 7500 support amid late-cycle market uneaseOct 20DEALSJNJ stock slips 6% despite Q3 earnings beat, MedTech missesOct 20EARNINGSNovo's CagriSema shows 25% weight loss in women in late-stage analysisOct 20EARNINGSTKO stock needs 11.7% annual growth to justify valuationOct 20ENERGYInflation hits consumer names while tech giants lead S&P 500 gainsOct 20WORLDUS federal budget deficit hits $2 trillion as debt servicing costs surgeOct 20MSCIMSCI Q3 2026 operating revenue rises 12.4% to $892 millionOct 20NVDANVIDIA fiscal Q2 revenue doubles to $96.22 billionOct 20WMTWalmart introduces discounted joint membership with Sam's ClubOct 20EARNINGSWedgewood Trims TSMC Position as Semiconductor Crowded Trade UnwindsOct 20EARNINGSS&P 500 tests 7500 support amid late-cycle market uneaseOct 20DEALSJNJ stock slips 6% despite Q3 earnings beat, MedTech missesOct 20EARNINGSNovo's CagriSema shows 25% weight loss in women in late-stage analysisOct 20EARNINGSTKO stock needs 11.7% annual growth to justify valuationOct 20ENERGYInflation hits consumer names while tech giants lead S&P 500 gainsOct 20WORLDUS federal budget deficit hits $2 trillion as debt servicing costs surgeOct 20MSCIMSCI Q3 2026 operating revenue rises 12.4% to $892 millionOct 20
NewsRegulatory · TOI

Starling Oncology taps SLR Healthcare ABL for $25 million revolving facility, draws $4.75 million at close

A $25 million revolving credit facility, priced at Term SOFR plus 3.95 percent and maturing August 20, 2029, is now in place at Starling Oncology, Inc. (Nasdaq: STLN) after its operating subsidiary closed the arrangement with Gemino Healthcare Finance, LLC on August 21, 2026. The direct borrower is Starling Oncology Management, LLC. At closing, $4.75 million was already outstanding.

By Talia GreenwoodNewsroomAugust 22, 20262 min readTOI
Share

Key takeaways

  • Starling Oncology, Inc. (Nasdaq: STLN) closed a $25 million revolving credit facility through its subsidiary Starling Oncology Management, LLC with Gemino Healthcare Finance, LLC (operating as SLR Healthcare ABL) on August 21, 2026.
  • Loans are priced at Term SOFR plus 3.95 percent, with Term SOFR set at the greater of the three-month rate or a 2.00 percent floor, and the facility matures August 20, 2029.
  • At closing, $4.75 million was already outstanding as an initial, partial draw against the $25 million capacity.
  • The facility carries a binding Maximum Loan Turn Days covenant capped at no more than 35 days on a rolling three-month basis, first measured December 31, 2026.
  • Availability is limited by an accounts-receivable formula, and the company states it is not required or expected to draw the full $25 million.

A $25 million revolving credit facility, priced at Term SOFR plus 3.95 percent and maturing August 20, 2029, is now in place at Starling Oncology, Inc. (Nasdaq: STLN) after its operating subsidiary closed the arrangement with Gemino Healthcare Finance, LLC on August 21, 2026. The direct borrower is Starling Oncology Management, LLC. At closing, $4.75 million was already outstanding.

Rate and fee structure

Gemino Healthcare Finance, operating as SLR Healthcare ABL, holds a first-priority security interest in substantially all of SOM, LLC's current and after-acquired collateral. Loans price at Term SOFR plus 3.95 percent. Term SOFR is the greater of the three-month forward-looking SOFR rate and a 2.00 percent floor, reset daily. Interest is due monthly on the first of each month. A default event would add 5.00 percent to the applicable rate.

A minimum balance concept applies: if outstanding loans fall below $5 million, a minimum use fee accrues at the full contract rate on that $5 million floor. Additional fees include a collateral monitoring charge of 0.0833 percent per month on the average borrowing base and an unused line fee of 0.04166 percent per month on the average undrawn balance. Termination carries a fee that steps down over the term: 3.00 percent of the $25 million commitment in year one, 2.00 percent in year two, 1.00 percent from the second anniversary through the August 2029 maturity.

The setup

Availability is not a straight draw. Borrowings must fit within a formula tied to accounts receivable, subject to periodic certification. Starling Oncology's 8-K states the facility is intended to provide financial flexibility if needed, and the company is not required or expected to draw the full $25 million. The $4.75 million outstanding at closing reflects an initial, partial draw against that capacity.

Three professional corporations in the Starling network (Starling Oncology CA, APC; The Oncology Institute FL, LLC; and Starling Oncology OR, a professional corporation) must enter lockbox arrangements over SOM, LLC's receivables. The binding operational covenant is a Maximum Loan Turn Days cap of no more than 35 days on a rolling three-month basis. Watch December 31, 2026: that is when the first quarterly measurement of that covenant falls due. The full Revolving Loan Agreement is attached as Exhibit 10.1 to the August 20 Form 8-K.

Related reading

About this story

Filed by the newsroom of MarketPR on August 22, 2026. Source: sec.gov. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Regulatory · MSCI

MSCI Q3 2026 operating revenue rises 12.4% to $892 million

MSCI Inc. (NYSE: MSCI) reported third-quarter 2026 operating revenues of $892.0 million, a 12.4% increase from the prior year period. The company stated that organic operating revenue growth reached 12.3% for the three months ended…

Renata Ostrowski2 min read
02Regulatory · DCOM

Dime Commercial Bancshares reports record quarterly revenue of $135 million

Dime Commercial Bancshares, Inc. (NYSE: DCOM) reported net income available to common stockholders of $39.7 million for the quarter ended September 30, 2026, a figure that equates to $0.90 per diluted common share. This result marks a 53%…

Grant Halloran2 min read
03Regulatory · INV

Innventure CFO Yablunosky transitions to consultant role

Innventure, Inc. has filed an 8-K reporting a change in control structure following the departure of its Chief Financial Officer, David Yablunosky. The company disclosed a consulting agreement dated October 19, 2026, which formalizes…

Renata Ostrowski2 min read

Frequently asked

Who is the lender and what security do they hold?

Gemino Healthcare Finance, LLC, operating as SLR Healthcare ABL, is the lender and holds a first-priority security interest in substantially all of SOM, LLC's current and after-acquired collateral.

How is the interest rate structured and what happens on default?

Loans price at Term SOFR (the greater of the three-month forward-looking SOFR or a 2.00 percent floor) plus 3.95 percent, with interest due monthly, and a default event adds 5.00 percent to the applicable rate.

What fees apply to the facility?

Fees include a collateral monitoring charge of 0.0833 percent per month on the average borrowing base, an unused line fee of 0.04166 percent per month on the average undrawn balance, a minimum use fee if loans fall below $5 million, and a termination fee that steps down from 3.00 percent to 1.00 percent over the term.

What operational conditions must the Starling network entities meet?

Three professional corporations—Starling Oncology CA, APC; The Oncology Institute FL, LLC; and Starling Oncology OR—must enter lockbox arrangements over SOM, LLC's receivables, and the facility requires a Maximum Loan Turn Days cap of no more than 35 days on a rolling three-month basis.

Where can the full loan agreement be found?

The full Revolving Loan Agreement is attached as Exhibit 10.1 to the company's August 20 Form 8-K.